0
0
Lifestyle and genetic advances are reshaping understanding of eye health, with digital strain driving rising vision problems in India while breakthroughs in gene and stem cell therapies offer new hope for inherited and degenerative conditions. Emerging research highlights both the growing public health burden of preventable eye diseases and transformative treatments on the horizon.
Rising Vision Crisis in India
India faces a significant and growing burden of vision impairment, with lifestyle changes playing a major role in deteriorating eye health, particularly among younger populations. According to the National Blindness and Visual Impairment Survey (2015–2019), approximately 6.2 million people in India are blind, and 55 million suffer from moderate to severe visual impairment. Alarmingly, over 75% of childhood visual impairments—9.3 million cases—are preventable or treatable, yet access to care remains a challenge, especially in rural areas where blindness is 1.37 times more prevalent than in urban regions.
One of the most concerning trends is the surge in myopia among young Indians. Urbanization, reduced outdoor activity, and excessive screen time are key contributors. Dr. Lalit Verma, president of the Asia Pacific Academy of Ophthalmology (APAO) 2025 Congress, has described the situation as a “silent epidemic,” noting that students now present with dry eye syndrome, eye strain, and early-onset squinting due to prolonged smartphone and digital device use. The 20-20-20 rule—taking a 20-second break every 20 minutes to look at something 20 feet away—is increasingly recommended to mitigate digital eye strain.
Environmental factors such as air pollution also exacerbate eye conditions. Mumbai-based ophthalmologist Dr. Minal Kanhere notes that urban populations face higher rates of dry eye disease due to pollutants like smoke and exhaust gases, which worsen allergic eye diseases. Meanwhile, rural populations remain vulnerable to infections and age-related diseases due to limited access to eye care services.
Breakthroughs in Genetic and Regenerative Therapies
While lifestyle-related eye problems are on the rise, scientific advances are offering unprecedented hope for treating inherited and degenerative eye diseases. Gene therapy has emerged as a transformative approach, particularly for inherited retinal diseases (IRDs), which affect 1 in 3,000 people globally and are caused by mutations in over 326 identified genes. Luxturna, the first FDA-approved gene therapy for an inherited retinal disease, has demonstrated sustained improvements in vision for patients with biallelic RPE65 mutations, with 72% of patients showing significant functional vision gains one year post-treatment.
Recent research continues to expand the genetic understanding of IRDs. Scientists have identified UBAP1L as a new gene linked to macular IRDs, including cone and cone-rod dystrophy, adding to the growing list of genetic targets for diagnosis and therapy. Nanoscope Therapeutics has reported promising results with MCO-010, a gene-agnostic optogenetic therapy that improved vision in patients with Stargardt disease and retinitis pigmentosa, suggesting potential for treating a broad range of IRDs regardless of the underlying genetic mutation.
Stem cell therapy is also making strides. A landmark study published in The Lancet demonstrated that induced pluripotent stem cell-derived corneal epithelial sheets (iCEPS) successfully restored functional vision in patients with limbal stem cell deficiency (LSCD), a condition that leads to corneal opacity and blindness. All four patients in the trial experienced significant visual improvement, with no severe adverse events reported over two years of follow-up. The use of allogeneic iCEPS without HLA matching suggests a future where stem cell grafts could be widely available without the need for donor matching or extensive immunosuppression.
Implications for Public Health and Future Directions
The dual challenge of rising preventable eye diseases and the promise of advanced therapies underscores the need for a comprehensive eye care strategy in India. Experts emphasize that while regenerative treatments offer hope for rare and severe conditions, public health efforts must focus on prevention, early diagnosis, and equitable access to care. Regular eye check-ups, lifestyle modifications, and public awareness campaigns are critical to curbing the myopia epidemic and reducing the burden of avoidable blindness.
Looking ahead, preclinical research in optogenetics and electrical stimulation shows potential for restoring vision in conditions like macular degeneration and glaucoma, with human trials expected to begin by 2028. Transpalpebral electrical stimulation (TES), a non-invasive technique, has already shown improved visual function in animal models of retinitis pigmentosa, suggesting a future where vision loss may be slowed or reversed without surgery.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
